Insulet Corporation (PODD) Fell Along with Broad Medtech Sector

1 month ago 19

Soumya Eswaran

Mon, July 13, 2026 astatine 8:49 AM CDT 2 min read

ClearBridge Investments, a planetary equity manager, precocious published second-quarter 2026 commentary for its "SMID Cap Growth Strategy". A transcript tin beryllium downloaded here. Small and mid-cap (SMID) maturation equities experienced the strongest 4th successful caller memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The Strategy delivered double-digit returns successful the 4th but trailed the soaring benchmark. Underperformance was driven by underexposure to apical AI infrastructure stocks arsenic good arsenic weaknesses successful healthcare and user discretionary sectors. The marketplace enactment expanded beyond mega-cap technology, indicating imaginable opportunities from a broader cyclical betterment and AI adoption. In addition, you tin cheque the Fund's apical 5 holdings to find its champion picks for 2026.

In its Q2 2026 capitalist letter, ClearBridge SMID Cap Growth Strategy highlighted Insulet Corporation (NASDAQ:PODD). Insulet Corporation (NASDAQ:PODD) is an American aesculapian instrumentality institution known for its Omnipod platform, an insulin transportation strategy for radical with insulin-dependent diabetes. On July 10, 2026, Insulet Corporation (NASDAQ:PODD) closed astatine $161.28 per share. One-month instrumentality of Insulet Corporation (NASDAQ:PODD) was 8.87%, and its shares mislaid 44.77% implicit the past 52 weeks. Insulet Corporation (NASDAQ:PODD) has a marketplace capitalization of $11.17 billion.

ClearBridge SMID Cap Growth Strategy stated the pursuing regarding Insulet Corporation (NASDAQ:PODD) successful its Q2 2026 capitalist update:

"Within wellness care, weakness successful supplier and prime aesculapian exertion holdings offset different coagulated contributions from biotechnology and beingness sciences tools holdings. Insulet Corporation (NASDAQ:PODD), the shaper of insulin spot pumps, besides detracted amid wide medtech weakness, insignificant merchandise callback and prime issues and rising concerns astir imaginable aboriginal competition."

Insulet Corporation (NASDAQ:PODD) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 55 hedge money portfolios held Insulet Corporation (NASDAQ:PODD) astatine the extremity of the archetypal quarter, compared to 60 successful the erstwhile quarter. In Q1 2026, Insulet Corporation (NASDAQ:PODD) generated revenue of $762 million, an summation of 34% connected a reported ground and 30% connected a changeless currency basis.While we admit the imaginable of Insulet Corporation (NASDAQ:PODD) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article